Phase 4 Type 2 Diabetes Trial, Recruiting NCT07442006 Sponsor: JW Pharmaceutical Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 4 Type 2 Diabetes Trial, Recruiting

NCT07442006
Recruiting Phase 4

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People with diabetes whose blood sugar levels are not well controlled even while taking Metformin (at a dose of at least 1,000mg per day) alongside an SGLT-2 inhibitor (a type of diabetes medication)

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have had a condition where dangerous levels of acid build up in the blood, either as a one-time event or an ongoing problem
  • People with moderate to severe kidney disease, where kidney function test results fall below a certain level (confirm with trial site)
  • People with severe liver disease or serious liver damage
  • People with a history of significant heart failure that causes noticeable to severe limitations on physical activity (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Sung Rae Kim, The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator

Phone: 82-2-840-6902

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
JW Pharmaceutical
Registry
ClinicalTrials.gov
Start date
29 October 2025
Est. completion
31 March 2027

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Mean change in Mean Amplitude of Glycemic Excursion (MAGE) from baseline to week 12

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov